PATIENT ALERT: Information regarding COVID-19. 

Clinical Research & Trials

Available Trials

Throughout the last century, the medical community has witnessed dramatic changes in the methods of diagnosis and treatment of cancer. Cancer research is no longer conducted exclusively at large university cancer centers or major metropolitan hospitals. Virginia Oncology Associates' physicians have embraced clinical cancer research as a critical component of community-based oncology care. Through a partnership with Duke University Oncology Consortium, National Cancer Institute, and US Oncology, VOA physicians are able to provide cancer patients with innovative treatment options and therapies. Virginia Oncology Associates offers the largest clinical research program in all of Hampton Roads. You do not have to leave the area to receive premier cancer care.

If you are interested in learning more about our research program, please call the VOA Research Department in the area closest to you:

Peninsula: (757) 873-9400

  • Hampton
  • Newport News
  • Williamsburg

Southside: (757) 466-8683

  • Norfolk
  • Virginia Beach


Breast Cancer Research

  • USO 21225

    A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Whose Disease is Resistant or Refractory to T-DM1, and/or T-DXd, and/or Tucatinib-containing Regimens (ACE-Breast-03)

    Available at 3 locations

    View Details

  • USO 20417

    A Phase IB/II, 2-Stage, Open-label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab (MEDI4736) + Paclitaxel and Durvalumab (MEDI4736) in Combination With Novel Oncology Therapies With or Without Paclitaxel for First-line Metastatic Triple Negative Breast Cancer (D933LC00001)

    Available at 4 locations

    View Details

  • D9673C00007 (DESTINY-Breast12)

    “An Open-Label, Multinational, Multicenter, Phase 3b/4 Study of Trastuzumab Deruxtecan in Patients With or Without Baseline Brain Metastasis With Previously-Treated Advanced/Metastatic HER2-Positive Breast Cancer(DESTINY-Breast12)”

    Available at 1 location

    View Details

  • USO 20431

    A Phase 3, Randomized, Double-Blind Study of Trilaciclib or Placebo in Patients Receiving First- or Second-Line Gemcitabine and Carboplatin Chemotherapy for Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (PRESERVE 2)(G1T28-208)

    Available at 1 location

    View Details

  • USO 19241

    A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy in the Metastatic Setting (DESTINY-Breast06) (D9670C00001)

    Available at 4 locations

    View Details

  • USO 20164

    A Phase II, Multicenter, Open Label Study Of Bintrafusp Alfa (M7824) Monotherapy In Participants With HMGA2-Expressing Triple Negative Breast Cancer (MS200647_0020)

    Available at 4 locations

    View Details

  • USO 19226

    A Phase Iii Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating The Efficacy And Safety Of Gdc-9545 Combined With Palbociclib Compared With Letrozole Combined With Palbociclib In Patients With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer (Bo41843)

    Available at 3 locations

    View Details

  • USO 19122

    A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Assess The Efficacy And Safety Of Alpelisib (BYL719) In Combination With Nab-Paclitaxel In Patients With Advanced Triple Negative Breast Cancer With Either Phosphoinositide-3-Kinase Catalytic Subunit Alpha (PIK3CA) Mutation Or Phosphatase And Tensin Homolog Protein (PTEN) Loss Without PIK3CA Mutation (CBYL719H12301)

    Available at 2 locations

    View Details

  • MERCK KEYLYNK MK7339-009

    An Open-label, Randomized, Phase 2/3 Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction of Clinical Benefit with First-line Chemotherapy Plus Pembrolizumab in Participants with Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (TNBC)(KEYLYNK-009)

    Available at 3 locations

    View Details

  • USO 17188

    A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK3475-KN756)

    Available at 3 locations

    View Details

GYN Cancer Research

  • USO 19156

    A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator’s Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer (SGNTV-003)

    Available at 2 locations

    View Details

  • USO 20398

    A Phase II, Open-Label, Multicenter, Platform Study Evaluating The Efficacy And Safety Of Biomarker-Driven Therapies In Patients With Persistent Or Recurrent Rare Epithelial Ovarian Tumors (Wo42178/Engot-Gyn2/Gog-3051)

    Available at 2 locations

    View Details

  • USO 20208

    An Open-Label Randomized Active-Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer (LAE002INT2001)

    Available at 1 location

    View Details

  • USO 19221

    A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Pa;clitaxel in Combination with Durvalumab, Followed by Maintenance Durvalumab with or without Olaparib in Patients with Newly Diagnosed Advanced or Recurrent Endometrial Cancer (DUO-E) (D9311C00001;GOG-3041; ENGOT-EN10)

    Available at 2 locations

    View Details

  • USO 18269

    Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields, 200kHz) Concomitant with Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer ( ENGOT-ov50 / INNOVATE-3)

    Available at 1 location

    View Details

Gastrointestinal Cancer Research

  • Alliance A021703

    A021703: Randomized Double-Blind Phase III Trial Of Vitamin D3 Supplementation In Patients With Previously Untreated Metastatic Colorectal Cancer (SOLARIS).

    Available at 5 locations

    View Details

  • USO 20235

    A Phase 3 Randomized, Double-blind Trial of Trilaciclib versus Placebo in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer: PRESERVE 1 (G1T28-207)

    Available at 4 locations

    View Details

  • USO 19245

    USO 19245: A Global, Multicenter, Randomized, Placebo-Controlled Phase 3 Trial To Compare The Efficacy And Safety Of Fruquintinib Plus Best Supportive Care To Placebo Plus Best Supportive Care In Patients With Refractory Metastatic Colorectal Cancer (FRESCO-2) (2019-013-GLOB1)

    Available at 3 locations

    View Details

Genitourinary Cancer Research

  • USO 20172

    A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

    Available at 1 location

    View Details

  • USO 20248

    A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)(67652000PCR3002)

    Available at 1 location

    View Details

  • USO 19236

    A Phase III, Multicenter, Randomized, Open-Label Study To Evaluate The Efficacy And Safety Of Atezolizumab Given In Combination With Cabozantinib Versus Cabozantinib Alone In Patients With Inoperable, Locally Advanced, Or Metastatic Renal Cell Carcinoma Who Experienced Radiographic Tumor Progression During Or After Immune Checkpoint Inhibitor Treatment (WO41994)

    Available at 3 locations

    View Details

  • USO 19144

    Biomarker Study To Determine Frequency Of DNA-Repair Defects In Men With Metastatic Prostate Cancer (64091742PCR0002)

    Available at 4 locations

    View Details

  • USO 18033

    A Phase 2 Study Of Sitravatinib In Combination With PD-(L)1 Checkpoint Inhibitor Regimens On Patients With Advanced Or Metastatic Urothelial Carcinoma (516-003)

    Available at 4 locations

    View Details

  • PSMA 301

    A prospective, Phase 3, Multi Center, Single-arm, Imaging Study Investigating The Safety And Diagnostic Performance Of rhPSMA 7.3 (18F) PET Ligand In Men With Newly Diagnosed Prostate Cancer (BED-PSMA-301)

    Available at 3 locations

    View Details

  • USO 17133

    A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR) (42756493BLC3001)

    Available at 1 location

    View Details

  • USO 18283

    A Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/PD-L1 Based Immunotherapy (IMMU-132-06)

    Available at 2 locations

    View Details

  • USO 18095

    A Phase 3, Randomized, Open-Label Study of Neoadjuvant Chemotherapy alone versus Neoadjuvant Chemotherapy plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post-Surgery Therapy with Nivolumab or Nivolumab and BMS-986205 in Participants with Muscle-Invasive Bladder Cancer (CA017078)

    Available at 4 locations

    View Details

Hematology

  • USO 20219

    A Dual-Cohort, Open-Label, Phase 2 Study Of Brentuximab Vedotin And CHP (A+CHP) In The Frontline Treatment Of Subjects With Peripheral T-Cell Lymphoma (PTCL) With Less Than 10% CD30 Expression (SGN35-032)

    Available at 5 locations

    View Details

  • USO 18177

    A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects with Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS) (ASTX727-03)

    Available at 1 location

    View Details

Leukemia & Lymphoma Research

  • USO 20133

    A Phase III, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) MOR208C310:

    Available at 5 locations

    View Details

  • USO 18281

    A Phase 1a/b Trial to Evaluate the Safety and Tolerability of CG-806 in Patients with CLL/SLL or Non-Hodgkin's Lymphomas (APTO-CG-806-01)

    Available at 1 location

    View Details

Lung Cancer Research

  • USO 19239

    A Phase 2, Randomized, Multicenter, Double-blind, Study of the Glutaminase Inhibitor Telaglenastat with Pembrolizumab and Chemotherapy versus Placebo with Pembrolizumab and Chemotherapy in First-line Metastatic KEAP1/NRF2-mutated Nonsquamous, Non-Small Cell Lung Cancer (NSCLC) CX-839-014 "KEAPSAKE":

    Available at 5 locations

    View Details

  • Astra Zeneca Adriatic (D933QC0001)

    A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with Limited Stage Small Cell- Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy (ADRIATIC)

    Available at 5 locations

    View Details

  • USO 20224

    Screening Protocol to Detect Mutation of KEAP1 or NRF2/NFE2L2 Genes in Patients with Non-Small Cell Lung Cancer Not Previously Treated for Metastatic Disease to Determine Eligibility for a Biomarker Selected Clinical Trial (KEAPSAKE Trial) (CX 839-016:)

    Available at 4 locations

    View Details

  • USO 20381

    Molecularly Informed Lung Cancer Treatment in a Community Cancer Network: A Pragmatic Prospective RWE Study (MYLUNG Consortium: Part 2)

    Available at 5 locations

    View Details

  • USO 20137

    A Phase III, Open-Label, Randomized Study Of Atezolizumab And Tiragolumab Compared With Durvalumab In Patients With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer Who Have Not Progressed After Concurrent Platinum-Based Chemoradiation (GO41854)

    Available at 5 locations

    View Details

  • USO 19109

    A Phase I Dose Escalation And Expanded Cohort Study Of Pf-06821497 In The Treatment Of Adult Patients With Relapsed/Refractory Small Cell Lung Cancer (Sclc), Castration Resistant Prostate Cancer (Crpc) And Follicular Lymphoma (Fl) (C2321001)

    Available at 1 location

    View Details

Multiple Myeloma

  • USO 19247

    A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant (54767414MMY3021)

    Available at 4 locations

    View Details

Solid Tumors Research

  • USO 20283

    A Phase 2 Study Of Brentuximab Vedotin In Combination With Pembrolizumab In Subjects With Metastatic Solid Malignancies After Progression On Prior PD-1 Inhibitor Treatment (SGN35-033)

    Available at 4 locations

    View Details

  • USO 19151

    A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001) STAR

    Available at 1 location

    View Details

  • BAYER LOXO 20810 (FORMERLY LOXO-EXT-17005)

    Phase 1/2 Study Of The TRK Inhibitor LOXO-195 In Adult And Pediatric Subjects With Previously Treated NTRK Fusion Cancers

    Available at 1 location

    View Details

  • Ignyta (RXDX 101-02)

    An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

    Available at 1 location

    View Details

Lymphoma & Hematologic

  • USO 19070

    Long-Term Follow-Up Protocol For Subjects Treated With Gene-Modified T Cells (Gc-Ltfu-001).

    Available at 1 location

    View Details